Business and Investor Opportunity

Vaccinogen: Revolutionizing Cancer Treatment with OncoVAX®

Vaccinogen is a pioneering research organization dedicated to the development of OncoVAX®, an autologous vaccine that holds the potential to transform the landscape of Colon Cancer treatment.  Our groundbreaking Phase III trial has demonstrated remarkable results. OncoVAX® showcased a significant 20% increase in disease-free survival over a decade for Stage 2 Colon Cancer patients, while reducing the risk of recurrence by 44% for all patients during a comprehensive five-year follow-up period.

This breakthrough in cancer treatment has far-reaching implications, with the potential to save millions of lives globally, not only in colon cancer but also in other adenocarcinomas. By investing in or partnering with Vaccinogen, you can contribute to this life-saving mission.

To propel the development of OncoVAX® further, we are seeking financing or partnership opportunities to complete the pivotal Phase IIIB trial. To successfully accomplish this milestone, an investment of $50M – $100M over a span of three to five years is required. We have already secured Fast Track designation and Special Protocol Assessment from the FDA, enabling us to perform an interim data analysis at 18 months. With these regulatory milestones in place, we anticipate FDA approval within three to four years.

Of particular importance, Vaccinogen holds a patent for our proprietary autologous vaccine technology, which grants us exclusive rights until 2039. This patent, numbered 11-351-235 and issued on 06/07/22, serves as a testament to the uniqueness and competitiveness of our approach.

As we move forward, Vaccinogen stands in a truly unique position. Our primary asset, the patent on “Autologous Vaccines and Methods,” has already yielded successful results in Phase IIIA clinical trials, focusing on minimal residual disease colon cancer. This achievement attests to the safety and efficacy of our approach, garnering further confidence in the potential of OncoVAX®.

To facilitate the critical technology transfer required for manufacturing the vaccines and conducting the Phase IIIB trial across the United States, Canada, and Western Europe, Vaccinogen has formed a consortium with two top-tier companies specializing in contract development and manufacturing (CDMO) and contract research (CRO). By assembling this consortium, we aim to expedite trial enrollment, with the first patient being enrolled within six to nine months of securing funding. Furthermore, this collaborative effort minimizes overhead costs and ensures efficient trial initiation.

In our pursuit of partners, we seek individuals and organizations willing to think outside the box and join us in the development, registration, and commercialization of OncoVAX®. Our vision extends beyond Stage 2 colon cancer, as we envision the potential of OncoVAX® in combination with standard care for more advanced stages of various adenocarcinomas. In fact, our Phase IIIB trial will explore the application of OncoVAX® in Stage 3 colon cancer, utilizing an FDA-approved protocol. Additionally, we foresee the development of Humon Monoclonal Antibodies (HuMabs) within OncoVAX® treated patients, potentially unlocking the ability to create adenocarcinoma vaccines for prevention. The neoepitopes coded by combinations of these HuMabs may very well be the key to unlocking new opportunities in cancer treatment.

By partnering with Vaccinogen, you will be at the forefront of personalized cancer immunotherapeutics, revolutionizing the way we combat this devastating disease. Join us on this extraordinary journey to make a lasting impact on the lives of patients and shape the future of cancer treatment.